Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Brachytherapy ; 16(3): 572-578, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28242194

RESUMO

PURPOSE: The quality of permanent prostate brachytherapy can be increased by addition of imaging modalities in the intraoperative procedure. This addition involves image registration, which inherently has inter- and intraobserver variabilities. We sought to quantify the inter- and intraobserver variabilities in geometry and dosimetry for contouring and image registration and analyze the results for our dynamic 125I brachytherapy procedure. METHODS AND MATERIALS: Five observers contoured 11 transrectal ultrasound (TRUS) data sets three times and 11 CT data sets one time. The observers registered 11 TRUS and MRI data sets to cone beam CT (CBCT) using fiducial gold markers. Geometrical and dosimetrical inter- and intraobserver variabilities were assessed. For the contouring study, structures were subdivided into three parts along the craniocaudal axis. RESULTS: We analyzed 165 observations. Interobserver geometrical variability for prostate was 1.1 mm, resulting in a dosimetric variability of 1.6% for V100 and 9.3% for D90. The geometric intraobserver variability was 0.6 mm with a V100 of 0.7% and D90 of 1.1%. TRUS-CBCT registration showed an interobserver variability in V100 of 2.0% and D90 of 3.1%. Intraobserver variabilities were 0.9% and 1.6%, respectively. For MRI-CBCT registration, V100 and D90 were 1.3% and 2.1%. Intraobserver variabilities were 0.7% and 1.1% for the same. CONCLUSIONS: Prostate dosimetry is affected by interobserver contouring and registration variability. The observed variability is smaller than underdosages that are adapted during our dynamic brachytherapy procedure.


Assuntos
Braquiterapia/métodos , Neoplasias da Próstata/diagnóstico por imagem , Neoplasias da Próstata/radioterapia , Tomografia Computadorizada de Feixe Cônico , Marcadores Fiduciais , Humanos , Radioisótopos do Iodo/uso terapêutico , Imageamento por Ressonância Magnética , Masculino , Variações Dependentes do Observador , Dosagem Radioterapêutica , Radioterapia Guiada por Imagem/métodos , Ultrassonografia
2.
Med Phys ; 44(4): 1257-1267, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28192614

RESUMO

PURPOSE: To evaluate adaptive planning for permanent prostate brachytherapy and to identify the prostate regions that needed adaptation. METHODS AND MATERIALS: After the implantation of stranded seeds, using real-time intraoperative planning, a transrectal ultrasound (TRUS)-scan was obtained and contoured. The positions of seeds were determined on a C-arm cone-beam computed tomography (CBCT)-scan. The CBCT-scan was registered to the TRUS-scan using fiducial gold markers. If dose coverage on the combined image-dataset was inadequate, an intraoperative adaptation was performed by placing remedial seeds. CBCT-based intraoperative dosimetry was analyzed for the prostate (D90, V100, and V150) and the urethra (D30). The effects of the adaptive dosimetry procedure for Day 30 were separately assessed. RESULTS: We analyzed 1266 patients. In 17.4% of the procedures, an adaptation was performed. Without the dose contribution of the adaptation Day 30 V100 would be < 95% for half of this group. On Day 0, the increase due to the adaptation was 11.8 ± 7.2% (1SD) for D90 and 9.0 ± 6.4% for V100. On Day 30, we observed an increase in D90 of 12.3 ± 6.0% and in V100 of 4.2 ± 4.3%. For the total group, a D90 of 119.6 ± 9.1% and V100 of 97.7 ± 2.5% was achieved. Most remedial seeds were placed anteriorly near the base of the prostate. CONCLUSION: CBCT-based adaptive planning enables identification of implants needing adaptation and improves prostate dose coverage. Adaptations were predominantly performed near the anterior base of the prostate.


Assuntos
Braquiterapia , Tomografia Computadorizada de Feixe Cônico , Neoplasias da Próstata/diagnóstico por imagem , Neoplasias da Próstata/radioterapia , Planejamento da Radioterapia Assistida por Computador/métodos , Humanos , Período Intraoperatório , Masculino , Radiometria , Dosagem Radioterapêutica
3.
Int J Radiat Oncol Biol Phys ; 96(1): 197-205, 2016 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-27325474

RESUMO

PURPOSE: We sought to identify the intraoperative displacement patterns of seeds and to evaluate the correlation of intraoperative dosimetry with day 30 for permanent prostate brachytherapy. METHODS AND MATERIALS: We analyzed the data from 699 patients. Intraoperative dosimetry was acquired using transrectal ultrasonography (TRUS) and C-arm cone beam computed tomography (CBCT). Intraoperative dosimetry (minimal dose to 40%-95% of the volume [D40-D95]) was compared with the day 30 dosimetry for both modalities. An additional edema-compensating comparison was performed for D90. Stranded seeds were linked between TRUS and CBCT using an automatic and fast linking procedure. Displacement patterns were analyzed for each seed implantation location. RESULTS: On average, an intraoperative (TRUS to CBCT) D90 decline of 10.6% ± 7.4% was observed. Intraoperative CBCT D90 showed a greater correlation (R(2) = 0.33) with respect to Day 30 than did TRUS (R(2) = 0.17). Compensating for edema, the correlation increased to 0.41 for CBCT and 0.38 for TRUS. The mean absolute intraoperative seed displacement was 3.9 ± 2.0 mm. The largest seed displacements were observed near the rectal wall. The central and posterior seeds showed less caudal displacement than lateral and anterior seeds. Seeds that were implanted closer to the base showed more divergence than seeds close to the apex. CONCLUSIONS: Intraoperative CBCT D90 showed a greater correlation with the day 30 dosimetry than intraoperative TRUS. Edema seemed to cause most of the systematic difference between the intraoperative and day 30 dosimetry. Seeds near the rectal wall showed the most displacement, comparing TRUS and CBCT, probably because of TRUS probe-induced prostate deformation.


Assuntos
Braquiterapia/instrumentação , Edema/etiologia , Migração de Corpo Estranho/etiologia , Hiperplasia Prostática/etiologia , Neoplasias da Próstata/radioterapia , Implantação de Prótese/efeitos adversos , Adulto , Idoso , Braquiterapia/métodos , Edema/diagnóstico por imagem , Migração de Corpo Estranho/diagnóstico por imagem , Humanos , Cuidados Intraoperatórios , Masculino , Pessoa de Meia-Idade , Movimento (Física) , Hiperplasia Prostática/diagnóstico por imagem , Neoplasias da Próstata/diagnóstico por imagem , Radiometria/métodos , Dosagem Radioterapêutica , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Resultado do Tratamento
4.
Radiother Oncol ; 119(1): 104-10, 2016 04.
Artigo em Inglês | MEDLINE | ID: mdl-26897512

RESUMO

BACKGROUND: Whole-gland salvage Iodine-125-brachytherapy is a potentially curative treatment strategy for localised prostate cancer (PCa) recurrences after radiotherapy. Prognostic factors influencing PCa-specific and overall survival (PCaSS & OS) are not known. The objective of this study was to develop a multivariable, internally validated prognostic model for survival after whole-gland salvage I-125-brachytherapy. MATERIALS AND METHODS: Whole-gland salvage I-125-brachytherapy patients treated in the Netherlands from 1993-2010 were included. Eligible patients had a transrectal ultrasound-guided biopsy-confirmed localised recurrence after biochemical failure (clinical judgement, ASTRO or Phoenix-definition). Recurrences were assessed clinically and with CT and/or MRI. Metastases were excluded using CT/MRI and technetium-99m scintigraphy. Multivariable Cox-regression was used to assess the predictive value of clinical characteristics in relation to PCa-specific and overall mortality. PCa-specific mortality was defined as patients dying with distant metastases present. Missing data were handled using multiple imputation (20 imputed sets). Internal validation was performed and the C-statistic calculated. Calibration plots were created to visually assess the goodness-of-fit of the final model. Optimism-corrected survival proportions were calculated. All analyses were performed according to the TRIPOD statement. RESULTS: Median total follow-up was 78months (range 5-139). A total of 62 patients were treated, of which 28 (45%) died from PCa after mean (±SD) 82 (±36) months. Overall, 36 patients (58%) patients died after mean 84 (±40) months. PSA doubling time (PSADT) remained a predictive factor for both types of mortality (PCa-specific and overall): corrected hazard ratio's (HR's) 0.92 (95% CI: 0.86-0.98, p=0.02) and 0.94 (95% CI: 0.90-0.99, p=0.01), respectively (C-statistics 0.71 and 0.69, respectively). Calibration was accurate up to 96month follow-up. Over 80% of patients can survive 8years if PSADT>24months (PCaSS) and >33months (OS). Only approximately 50% survival is achieved with a PSADT of 12months. CONCLUSION: A PSADT of respectively >24months and >33months can result in >80% probability of PCa- specific and overall survival 8years after whole-gland salvage I-125-brachytherapy. Survival should be weighed against toxicity from a salvage procedure. Larger series and external validation are necessary.


Assuntos
Braquiterapia/métodos , Radioisótopos do Iodo/uso terapêutico , Neoplasias da Próstata/radioterapia , Idoso , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Neoplasias da Próstata/mortalidade , Neoplasias da Próstata/patologia , Terapia de Salvação/métodos
5.
Brachytherapy ; 15(1): 85-93, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26614233

RESUMO

PURPOSE: Organ-confined prostate cancer recurrences after primary radiotherapy can be treated with salvage iodine-125 brachytherapy. Options include total salvage (TS) or focal salvage (FS). TS often leads to severe late gastrointestinal (GI) toxicity. Differences in rectal dosimetry between TS and FS are presented and dose constraints proposed to reduce late severe GI toxicity (>90 days). METHODS AND MATERIALS: Intraoperative dosimetry and 30-day CT-dosimetry of 20 FS and 28 TS patients were evaluated. GI toxicity was evaluated using the common terminology criteria for adverse events-4. With receiver operating characteristic analysis, dosimetry cutoff values to prevent severe late GI toxicity were assessed. RESULTS: FS reduces rectal dose significantly. Median D(0.1cc), D(1cc), D(2cc), and V100 reductions were 38 Gy (p = 0.002), 46 Gy (p < 0.0001), 46 Gy (p < 0.0001), and 0.41 cc (p = 0.0001), respectively, compared with TS. FS patients had no late severe GI toxicity. TS patients with severe GI toxicity (41%, n = 11) showed significantly higher rectal doses than TS patients without GI toxicity (59%, n = 16). Median D(0.1cc), D(1cc), D(2cc), and V100 differences were 29 Gy (p < 0.001), 17 Gy (p = 0.001), 28 Gy (p < 0.001), and 0.45 cc (p = 0.001). With receiver operating characteristic analysis, restrictions for the D(0.1cc), D(1cc), D(2cc), and V100 are <160 Gy (area under the curve [AUC], 0.88; 95% confidence interval [CI] 0.76-1.00), <119 Gy (AUC, 0.87; 95% CI, 0.74-1.00), <102 Gy (AUC, 0.89; 95% CI, 0.77-1.00), and <0.38 cc (AUC, 0.88; 95% CI, 0.75-1.00), respectively. Thirty-day CT dosimetry showed minor overestimation of intraoperative D(2cc) (median, 10 Gy [p = 0.02]). CONCLUSIONS: FS reduces rectal dose compared with TS. D(0.1cc), D(1cc), D(2cc), and V100 restrictions were 160 Gy, 120 Gy, 100 Gy, and 0.35 cc. Taking correlation into account, the D2cc <100 Gy might be sufficient for clinical practice. Larger series and multivariable models are necessary to further assess the found restrictions.


Assuntos
Braquiterapia/métodos , Radioisótopos do Iodo/uso terapêutico , Recidiva Local de Neoplasia/radioterapia , Neoplasias da Próstata/radioterapia , Lesões por Radiação/etiologia , Reto/efeitos da radiação , Terapia de Salvação/métodos , Idoso , Área Sob a Curva , Braquiterapia/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Órgãos em Risco , Neoplasias da Próstata/patologia , Curva ROC , Doses de Radiação , Dosagem Radioterapêutica , Terapia de Salvação/efeitos adversos
6.
Brachytherapy ; 13(2): 128-36, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24041955

RESUMO

PURPOSE: To present a high-dose-rate (HDR) brachytherapy procedure for prostate cancer using transrectal ultrasound (TRUS) to contour the regions of interest and registered in-room cone-beam CT (CBCT) images for needle reconstruction. To characterize the registration uncertainties between the two imaging modalities and explore the possibility of performing the procedure solely on TRUS. METHODS AND MATERIALS: Patients were treated with a TRUS/CBCT-based HDR brachytherapy procedure. For 100 patients, dosimetric results were analyzed. For 40 patients, registration uncertainties were examined by determining differences in fiducial marker positions on TRUS and registered CBCT. The accuracy of needle reconstruction on TRUS was investigated by determining the position differences of needle tips on TRUS and CBCT. The dosimetric impact of reregistration and needle reconstruction on TRUS only was studied for 8 patients. RESULTS: The average prostate V100 was 97.8%, urethra D10 was 116.3%, and rectum D1 cc was 66.4% of the prescribed dose. For 85% of the patients, registration inaccuracies were within 3 mm. Large differences were found between needle tips on TRUS and CBCT, especially in cranial-caudal direction, with a maximum of 10.4 mm. Reregistration resulted in a maximum V100 reduction of 0.9%, whereas needle reconstruction on TRUS only gave a maximum reduction of 9.4%. CONCLUSIONS: HDR prostate brachytherapy based on TRUS combined with CBCT is an accurate method. Registration uncertainties, and consequently dosimetric inaccuracies, are small compared with the uncertainties of performing the procedure solely based on static TRUS images. CBCT imaging is a requisite in our current procedure.


Assuntos
Braquiterapia/métodos , Neoplasias da Próstata/radioterapia , Tomografia Computadorizada de Feixe Cônico , Humanos , Masculino , Agulhas , Neoplasias da Próstata/diagnóstico por imagem , Radiometria/métodos , Reto/diagnóstico por imagem , Reto/efeitos da radiação , Estudos Retrospectivos , Uretra/diagnóstico por imagem , Uretra/efeitos da radiação
7.
Brachytherapy ; 11(5): 327-33, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-21816685

RESUMO

PURPOSE: To present an objective automated method to determine time trends in prostatic edema resulting from iodine-125 brachytherapy. METHODS AND MATERIALS: We followed 20 patients, implanted with stranded seeds, with seven consecutive CT scans to establish a time trend in prostate edema. Seed positions were obtained automatically from the CT series. The change in seed positions was used as surrogate for edema. Two approaches were applied to model changes in volume. (1) A cylindrical model: seeds from the compared distribution were linked to the reference distribution of Day 28. After alignment, the compared distribution was scaled in cylindrical coordinates, leading to the changes in radial and craniocaudal directions. The volume changes were calculated using these scaling factors. (2) A spherical model: distances of seeds to the center of gravity of all seeds were used as a measure to model volume changes. RESULTS: With Day 28 as reference, the observed volume changes were smaller than 18% ± 6% (1 standard deviation) for the cylindrical model and 12% ± 7% for the spherical model. One day after implantation, the implanted prostate was less than 10% larger than in the reference scan for both models. Apart from Day 0, both models showed similar volume changes. CONCLUSIONS: We present an objective automated method to determine changes in the implanted prostate volume, eliminating the influence of an observer in the assessment of the prostate size. The implanted volume change was less than 18% ± 7% for the studied group of 20 patients. Edema was 9% ± 5% from 1 day after implantation onward.


Assuntos
Braquiterapia/efeitos adversos , Edema/patologia , Modelos Teóricos , Doenças Prostáticas/patologia , Edema/diagnóstico por imagem , Humanos , Radioisótopos do Iodo , Masculino , Tamanho do Órgão/efeitos da radiação , Doenças Prostáticas/diagnóstico por imagem , Fatores de Tempo , Tomografia Computadorizada por Raios X
8.
Radiat Oncol ; 2: 40, 2007 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-17971196

RESUMO

BACKGROUND: The standard treatment of the axilla in breast cancer used to be an axillary lymph node dissection. An axillary lymph node dissection is known to give substantial risks of morbidity. In recent years the sentinel node biopsy has become common practice. Future randomized study results will determine whether the expected decrease in morbidity can be proven. METHODS: Before the introduction of the sentinel node biopsy, we conducted a study in which 180 women of 50 years and older with T1/T2 cN0 breast cancer were treated with breast conserving therapy. Instead of an axillary lymph node dissection regional radiotherapy was given in combination with tamoxifen (RT-group). The study group was compared with 341 patients, with the same patient and tumour characteristics, treated with an axillary lymph node dissection (S-group). RESULTS: The treatment groups were comparable, except for age. The RT-group was significantly older than the S-group. The median follow up was 7.2 years. The regional relapse rates were low and equal in both treatment groups, 1.1% in RT-group versus 1.5% in S-group at 5 years. The overall survival was similar; the disease free survival was significant better in the RT-group. CONCLUSION: Regional recurrence rates after regional radiotherapy are very low and equal to an axillary lymphnode dissection.


Assuntos
Neoplasias da Mama/radioterapia , Neoplasias da Mama/cirurgia , Excisão de Linfonodo , Idoso , Neoplasias da Mama/mortalidade , Neoplasias da Mama/patologia , Estudos de Casos e Controles , Terapia Combinada , Feminino , Seguimentos , Humanos , Mastectomia Segmentar/métodos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Radioterapia/métodos , Estudos Retrospectivos , Biópsia de Linfonodo Sentinela , Análise de Sobrevida , Sobreviventes , Tamoxifeno/uso terapêutico , Fatores de Tempo
9.
Brachytherapy ; 6(4): 231-7, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17991620

RESUMO

PURPOSE: (1) To demonstrate the feasibility of C-arm cone-beam computed tomography (CBCT)-based postplanning and subsequent adaptation of underdosed critical areas by adding remedial seeds during the transrectal ultrasound (TRUS)-guided implantation of (125)I seeds and (2) to assess the duration of this procedure. METHODS AND MATERIALS: After finishing the implant, three fiducial markers were implanted and a TRUS study was performed to delineate the prostate. A C-arm CBCT unit with isocentric design was used to generate a CT data set to localize the seeds. The TRUS and CBCT data sets were coregistered by the radiation oncologist to assess the dosimetry of the implant. If underdosages existed at critical areas, dosimetry was adapted by adding remedial seeds while the patient was still under anesthesia. RESULTS: Of 20 patients studied, 9 demonstrated underdosage in critical areas. On average four additional seeds were implanted, resulting in a mean D(90) of 100.7% (increase 4.9%) and 117.5% (increase 17.8%) of the prescribed dose of 145 and 110 Gy, respectively. The average additional time involved in performing the adaptation procedure was less than 30 min. CONCLUSIONS: C-arm CBCT-guided intraoperative postplanning during TRUS-guided brachytherapy for prostate cancer is both feasible and time efficient. The adaptation resulted in improved dosimetry of the prostate implants.


Assuntos
Braquiterapia/métodos , Radioisótopos do Iodo/administração & dosagem , Neoplasias da Próstata/radioterapia , Tomografia Computadorizada de Feixe Cônico , Estudos de Viabilidade , Humanos , Radioisótopos do Iodo/uso terapêutico , Masculino , Próstata , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...